What is Klone Lab?
Klone Lab operates as a premier full-service licensing entity, specializing in the end-to-end design, manufacture, and distribution of high-performance sport and lifestyle sandals, golf footwear, and advanced biomechanical solutions. The company serves as a critical partner for global sports and lifestyle brands, providing the infrastructure necessary to enhance brand portfolios and unlock new market opportunities. Beyond its licensing operations, Klone Lab maintains a proprietary edge through the development of brands such as Revitalign, which integrates biomechanical engineering with consumer-facing lifestyle aesthetics. Their comprehensive service model encompasses the entire value chain, from initial design and sourcing to final market distribution, ensuring that partner brands maintain a competitive advantage in a rapidly evolving retail landscape.
How much funding has Klone Lab raised?
Klone Lab has raised a total of $349K across 2 funding rounds:
Debt
$150K
Debt
$199K
Debt (2020): $150K with participation from PPP
Debt (2021): $199K led by PPP
Key Investors in Klone Lab
PPP
Public-Private Partnership
What's next for Klone Lab?
With the recent influx of capital, Klone Lab is well-positioned to accelerate its strategic expansion into emerging market segments and further refine its biomechanical footwear technology. The company is expected to prioritize the scaling of its licensing partnerships, leveraging its deep industry expertise to capture additional market share within the athletic footwear category. Future initiatives will likely focus on optimizing supply chain efficiencies and expanding the reach of its internal brand portfolio, ensuring that the firm remains at the forefront of footwear innovation. As the company transitions through this late-stage growth phase, the focus will remain on maintaining operational excellence while exploring new avenues for brand development and global distribution.
See full Klone Lab company page
